WO2003093418A3 - Keratinocytes expressing exogenous angiogenic growth factors - Google Patents

Keratinocytes expressing exogenous angiogenic growth factors Download PDF

Info

Publication number
WO2003093418A3
WO2003093418A3 PCT/US2003/013327 US0313327W WO03093418A3 WO 2003093418 A3 WO2003093418 A3 WO 2003093418A3 US 0313327 W US0313327 W US 0313327W WO 03093418 A3 WO03093418 A3 WO 03093418A3
Authority
WO
WIPO (PCT)
Prior art keywords
growth factors
angiogenic growth
expressing exogenous
keratinocytes
skin tissue
Prior art date
Application number
PCT/US2003/013327
Other languages
French (fr)
Other versions
WO2003093418A2 (en
Inventor
Allen Comer
Michael Hoffmann
Lynn-Allen Hoffmann
Original Assignee
Stratech Corp
Allen Comer
Michael Hoffmann
Lynn-Allen Hoffmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP03726524A priority Critical patent/EP1549738B1/en
Priority to AU2003228755A priority patent/AU2003228755B2/en
Priority to DE60332256T priority patent/DE60332256D1/en
Priority to NZ536205A priority patent/NZ536205A/en
Priority to CA2483547A priority patent/CA2483547C/en
Priority to AT03726524T priority patent/ATE465242T1/en
Application filed by Stratech Corp, Allen Comer, Michael Hoffmann, Lynn-Allen Hoffmann filed Critical Stratech Corp
Priority to IL16481703A priority patent/IL164817A0/en
Priority to JP2004501554A priority patent/JP4753577B2/en
Publication of WO2003093418A2 publication Critical patent/WO2003093418A2/en
Priority to IL164817A priority patent/IL164817A/en
Publication of WO2003093418A3 publication Critical patent/WO2003093418A3/en
Priority to IL195518A priority patent/IL195518A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • C12N5/0698—Skin equivalents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/17—Angiopoietin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/09—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells
    • C12N2502/094—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells keratinocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1323—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Abstract

The present invention relates to in vitro cultured skin tissue, and in particular to cultured skin tissue comprising exogenous genes encoding angiogenic growth factors. In some embodiments, the keratinocytes express exogenous angiopoietin-1 or a member of the VEGF family, preferably VEGF-A. In particularly preferred embodiments, the keratinocytes are incorporated into cultured skin tissue.
PCT/US2003/013327 2002-04-30 2003-04-29 Keratinocytes expressing exogenous angiogenic growth factors WO2003093418A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2003228755A AU2003228755B2 (en) 2002-04-30 2003-04-29 Keratinocytes expressing exogenous angiogenic growth factors
DE60332256T DE60332256D1 (en) 2002-04-30 2003-04-29 EXOGENOUS ANGIOGENIC GROWTH FACTORS EXPRESSIVE KERATINOCYTES
NZ536205A NZ536205A (en) 2002-04-30 2003-04-29 Keratinocytes expressing exogenous angiogenic growth factors
CA2483547A CA2483547C (en) 2002-04-30 2003-04-29 Keratinocytes expressing exogenous angiogenic growth factors
AT03726524T ATE465242T1 (en) 2002-04-30 2003-04-29 EXOGENEOUS ANGIOGENIC GROWTH FACTORS EXPRESSING KERATINOCYTES
EP03726524A EP1549738B1 (en) 2002-04-30 2003-04-29 Keratinocytes expressing exogenous angiogenic growth factors
IL16481703A IL164817A0 (en) 2002-04-30 2003-04-29 Keratinocytes expressing exogenous angiogenic growth factors
JP2004501554A JP4753577B2 (en) 2002-04-30 2003-04-29 Keratinocytes expressing exogenous angiogenic growth factors
IL164817A IL164817A (en) 2002-04-30 2004-10-25 Composition comprising near diploid immortalized keratinocytes cells
IL195518A IL195518A (en) 2002-04-30 2008-11-25 Skin graft composition comprising near diploid immortalized keratinocyte (niks) cells and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37648802P 2002-04-30 2002-04-30
US60/376,488 2002-04-30
US10/425,784 2003-04-29
US10/425,784 US7498167B2 (en) 2002-04-30 2003-04-29 Keratinocytes expressing exogenous angiogenic growth factors

Publications (2)

Publication Number Publication Date
WO2003093418A2 WO2003093418A2 (en) 2003-11-13
WO2003093418A3 true WO2003093418A3 (en) 2005-04-21

Family

ID=29406758

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/013327 WO2003093418A2 (en) 2002-04-30 2003-04-29 Keratinocytes expressing exogenous angiogenic growth factors

Country Status (9)

Country Link
US (5) US7498167B2 (en)
EP (1) EP1549738B1 (en)
JP (1) JP4753577B2 (en)
AT (1) ATE465242T1 (en)
CA (1) CA2483547C (en)
DE (1) DE60332256D1 (en)
IL (3) IL164817A0 (en)
NZ (1) NZ536205A (en)
WO (1) WO2003093418A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL164817A0 (en) 2002-04-30 2005-12-18 Stratatech Corp Keratinocytes expressing exogenous angiogenic growth factors
CA2600177C (en) 2005-03-01 2011-06-14 Stratatech Corporation Human skin equivalents expressing exogenous polypeptides
EP2215212B1 (en) 2007-11-14 2017-08-30 Stratatech Corporation Cold storage of organotypically cultured skin equivalents for clinical applications
DK2352472T3 (en) 2008-11-04 2017-04-10 Stratatech Corp Dried and irradiated skin equivalents ready to use
US20100330046A1 (en) * 2009-05-21 2010-12-30 Stratatech Corporation Human skin substitutes expressing il-12
TWI488966B (en) * 2010-07-09 2015-06-21 優普生物科技股份有限公司 Dna vaccine
US8978234B2 (en) 2011-12-07 2015-03-17 MoMelan Technologies, Inc. Methods of manufacturing devices for generating skin grafts
US9597111B2 (en) 2010-08-06 2017-03-21 Kci Licensing, Inc. Methods for applying a skin graft
JP2012205516A (en) * 2011-03-29 2012-10-25 Osaka Univ Method for producing artificial skin model, and artificial skin model
US20140065110A1 (en) * 2012-08-31 2014-03-06 The Regents Of The University Of California Genetically modified msc and therapeutic methods
US9663564B2 (en) 2013-03-15 2017-05-30 The Regents Of The University Of California Vectors and methods to treat ischemia
WO2014072941A1 (en) 2012-11-09 2014-05-15 Marco Archetti Diffusible factors and cancer cells
ES2705043T3 (en) 2013-03-13 2019-03-21 Stratatech Corp Cryopreservation of viable human skin substitutes
CN105636532B (en) 2013-03-14 2019-06-21 凯希特许有限公司 For acquiring the absorbability substrate of skin graft
EP3089682B1 (en) 2013-12-31 2017-04-19 KCI Licensing, Inc. Sensor systems for skin graft harvesting
US10463392B2 (en) 2013-12-31 2019-11-05 Kci Licensing, Inc. Fluid-assisted skin graft harvesting
WO2016164890A1 (en) 2015-04-09 2016-10-13 Kci Licensing, Inc. Soft-tack, porous substrates for harvesting skin grafts
WO2017079439A1 (en) 2015-11-03 2017-05-11 Kci Licensing, Inc. Device for creating an epidermal graft sheet
WO2017143229A1 (en) * 2016-02-19 2017-08-24 Kci Licensing, Inc. Transfected epidermal grafts and methods of making the same
EP3551746A1 (en) * 2016-12-09 2019-10-16 The University of Chicago Tissue organoids
EP4034038A4 (en) * 2019-09-27 2023-11-01 Stratatech Corporation Methods for treating acute wounds and improving outcomes
WO2021231775A1 (en) * 2020-05-13 2021-11-18 Stratatech Copporation Viable bioengineered skin constructs
AU2022287965A1 (en) * 2021-06-08 2023-12-14 Stratatech Corporation Viable bioengineered allogeneic cellularized skin constructs that secrete soluble factors associated with regenerative wound healing
WO2023017494A1 (en) * 2021-08-13 2023-02-16 Triovance Holding Llc A skin substitute composition and methods of producing and using the same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US448096A (en) * 1891-03-10 Hydrant
US4485096A (en) 1982-02-26 1984-11-27 Massachusetts Institute Of Technology Tissue-equivalent and method for preparation thereof
IL95429A (en) 1989-09-15 1997-09-30 Organogenesis Living tissue equivalents comprising hydrated collagen lattice and a collagen gel and their production
US5292655A (en) * 1990-01-29 1994-03-08 Wille Jr John J Method for the formation of a histologically-complete skin substitute
HUT63319A (en) 1990-04-24 1993-08-30 Mark Eisenberg Method for producing composition equivalent with living skin
US5292566A (en) * 1990-05-22 1994-03-08 National Label Company Battery label with non-shrinkable top layer
IT1248934B (en) 1990-06-01 1995-02-11 Fidia Spa BIOCOMPATIBLE PERFORATED MEMBRANES, PROCESSES FOR THEIR PREPARATION, THEIR USE AS A SUPPORT FOR THE IN VITRO GROWTH OF EPITHELIAL CELLS, ARTIFICIAL LEATHER THUS OBTAINED AND THEIR USE IN LEATHER TRANSPLANTS
US5693332C1 (en) 1995-08-11 2001-01-09 Univ California Human keratinocytes supported on a hydrophilic membrane and methods of using same to effect wound closure
US5968546A (en) 1997-05-16 1999-10-19 Baur; Marcus Keratinocyte culture from precursor cells
US20010048917A1 (en) * 1998-03-09 2001-12-06 Warren Hoeffler Skin equivalent and methods of forming and using same
US5989837A (en) 1998-07-13 1999-11-23 Wisconsin Alumni Research Foundation Immortalized human keratinocyte cell line
US20030152562A1 (en) * 2001-10-23 2003-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Vitro micro-organs, and uses related thereto
US6458382B1 (en) * 1999-11-12 2002-10-01 Mirus Corporation Nucleic acid transfer complexes
AU2002224471A1 (en) * 2000-11-01 2002-05-15 Aventis Pharma S.A. In vivo stimulation of angiogenic activity
EP1404809B1 (en) * 2001-03-02 2013-12-11 Stratatech Corporation Improved skin substitutes and uses thereof
US6849718B2 (en) 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
WO2003018621A2 (en) * 2001-08-23 2003-03-06 Oxford Biomedica (Uk) Limited Genes
US6838430B2 (en) 2001-09-28 2005-01-04 The Regents Of The University Of California Use of HIF-1a variants to accelerate wound healing
US20040190793A1 (en) 2002-03-01 2004-09-30 Rorvig Mark E. Method for retrieving images by content measure metadata encoding
IL164817A0 (en) 2002-04-30 2005-12-18 Stratatech Corp Keratinocytes expressing exogenous angiogenic growth factors
US7462448B2 (en) 2002-08-02 2008-12-09 Stratatech Corporation Species specific DNA detection
CA2527822A1 (en) 2003-05-30 2004-12-23 Stratatech Corporation Room temperature storage of organs
EP3100611B1 (en) 2003-08-01 2018-09-12 Stratatech Corporation Human skin equivalents expressing exogenous polypeptides

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALLEN-HOFFMANN ET ALL: "Normal Growth and Differentiation in a Spontaneously Immunortalized Near-diploid Human Keratinocyte Cell Line, NIKS", J INVEST DERMATOL, vol. 114, no. 3, March 2004 (2004-03-01), pages 444 - 455, XP002964029 *
DETMAR M. ET AL: "Hypoxia Regulates the Expression of Vascular Permeability Factor/vascular Endothelial Growth Factor (VPF/VEGF) and Its Receptors in Human Skin", J INVEST DERMATOL, vol. 108, no. 3, March 1997 (1997-03-01), pages 263 - 268, XP002924630 *
RIO M.D ET AL: "Nonviral Transfer of Genes to Pig Primary Keratinocytes. Induction of Angiogenesisby Composite Grafts of Modified Keratinocytes Overexpressing VEGF Driven by a Keratin Promotor", GENE THERAPY, vol. 6, October 1999 (1999-10-01), pages 1734 - 1741, XP008049910 *

Also Published As

Publication number Publication date
EP1549738B1 (en) 2010-04-21
CA2483547C (en) 2012-03-20
EP1549738A2 (en) 2005-07-06
US7915042B2 (en) 2011-03-29
WO2003093418A2 (en) 2003-11-13
IL195518A (en) 2012-08-30
AU2003228755A1 (en) 2003-11-17
CA2483547A1 (en) 2003-11-13
IL164817A (en) 2010-12-30
US20040009591A1 (en) 2004-01-15
US7807148B2 (en) 2010-10-05
JP4753577B2 (en) 2011-08-24
IL164817A0 (en) 2005-12-18
US20110286985A1 (en) 2011-11-24
US20110059057A1 (en) 2011-03-10
US7498167B2 (en) 2009-03-03
ATE465242T1 (en) 2010-05-15
EP1549738A4 (en) 2006-11-02
DE60332256D1 (en) 2010-06-02
JP2006509529A (en) 2006-03-23
US20090169528A1 (en) 2009-07-02
US20050013807A1 (en) 2005-01-20
US7988959B2 (en) 2011-08-02
NZ536205A (en) 2008-04-30
US8808685B2 (en) 2014-08-19

Similar Documents

Publication Publication Date Title
WO2003093418A3 (en) Keratinocytes expressing exogenous angiogenic growth factors
WO2005012492A8 (en) Human skin equivalents expressing exogenous polypeptides
WO2004048545A3 (en) DELIVERY OF siRNAs______________________________________________
WO2002007679A3 (en) Adult human dental pulp stem cells in vitro and in vivo
WO2004007695A3 (en) Lactobacilli expressing biologically active polypeptides and uses thereof
WO1997049827A3 (en) Adenoviral mediated gene transfer in adipocytes and related implants
EP1536828A4 (en) Methods of delivery of exogenous proteins to the cytosol and uses thereof
WO2006094070A3 (en) Human skin equivalents expressing exogenous polypeptides
WO2003060085A3 (en) Mammalian neural stem cells, compositions and uses thereof
EP1459759A4 (en) Drug mobilizing pluripotent stem cells from tissue into peripheral blood
AU2001277539A1 (en) Pre-adipose cell lines
DE60036537D1 (en) COMPOSITIONS FOR GENETHERAPY OF DIABETES
AU2001270484A1 (en) Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations
WO2001068828A3 (en) Compositions and methods for regulated protein expression in gut
WO2005052140A3 (en) Multipotent postnatal stem cells from human periodontal ligament and uses thereof
WO2002050111A3 (en) Isolated laminin 10
WO2002098361A3 (en) T cell induced tissue repair and regeneration
AU2002224471A1 (en) In vivo stimulation of angiogenic activity
WO2007088051A3 (en) Modulation of mdl-1 activity for treatment of inflammatory disease
AU2000240061A1 (en) Tissue compositions using cultured fibroblasts and keratinocytes and methods of use thereof
WO2002030443A3 (en) Regulation of human skin healing
WO2001072781A3 (en) Human genes and expression products
WO2002012336A3 (en) TGF-β THERAPEUTICS, COMPOSITIONS AND METHODS OF USE
AU2003272159A8 (en) Bicistronic vector encoding a vegf and an fgf, use thereof
AU7042000A (en) Recombinant yeast strain for expressing human lactoferrin, n-lobe lactoferrin, c-lobe lactoferrin and process for preparation recombinant human lactoferrin, n-lobe lactoferrin, c-lobe lactoferrin using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2483547

Country of ref document: CA

Ref document number: 2003228755

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 536205

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004501554

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003726524

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003726524

Country of ref document: EP